Fragile X-Associated Disorders: Illuminating the Spectrum of Disease Through Molecular, Clinical, and Therapeutic Advances

Hagerman, Randi J.

Symposium 28 (open)
Fragile X-Associated Disorders: Illuminating the Spectrum of Disease Through Molecular, Clinical, and Therapeutic Advances

Friday, October 24, 2014: 8:30 AM-11:30 AM

Chair:

Randi J. Hagerman, MD

28.1

Fragile X Premutation: From Neurodevelopmental to Neurodegenerative Disorders
Randi J. Hagerman, MD University of California, Davis Health System, Endowed Chair in Fragile X Research, Sacramento, CA

28.2

Next-Generation Fragile X PCR: Breaking Barriers to Enable Comprehensive FMR1 Molecular Analyses From Patient-Friendly Specimens
Gary J. Latham, PhD Asuragen Inc., Austin, TX

28.3

Molecular-Clinical Profiles in Fragile X: Novel FMR1 Genetic and Epigenetic Molecular Assessments in a Cohort of Full-Mutation and Premutation Patients
Dejan B. Budimirovic, MD Clinical Trials Center, Kennedy Krieger Institute, The Johns Hopkins Medical Institutions, Baltimore, MD

28.4

Identifying New Targets of Treatment: Potential Molecular Mediators of Dendritic Overgrowth in Fragile X Syndrome
Craig A. Erickson, MD Cincinnati Children's Hospital Medical Center, Cincinnati, OH

See more of: Symposium

61st Annual Meeting

October 18 - 25, 2014

Program Navigation

Symposium 28 (open)
Fragile X-Associated Disorders: Illuminating the Spectrum of Disease Through Molecular, Clinical, and Therapeutic Advances

Symposium 28 (open) Fragile X-Associated Disorders: Illuminating the Spectrum of Disease Through Molecular, Clinical, and Therapeutic Advances

Symposium 28 (open)
Fragile X-Associated Disorders: Illuminating the Spectrum of Disease Through Molecular, Clinical, and Therapeutic Advances